Catalyst Pharmaceuticals (CPRX) Long-Term Deferred Tax (2012 - 2026)

Catalyst Pharmaceuticals has reported Long-Term Deferred Tax for 11 years, with the latest figure at $55.1 million in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Deferred Tax rose 14.29% year-over-year to $55.1 million; the trailing twelve-month figure through Mar 2026 stood at $55.1 million (up 14.29% YoY), and the FY2025 full-year result was $52.8 million, up 14.76% from the prior year.
• Long-Term Deferred Tax for Q1 2026 stood at $55.1 million, up from $52.8 million in the prior quarter.
• The five-year high for Long-Term Deferred Tax was $55.1 million in Q1 2026, with the low at $18.7 million in Q4 2022.
• Historically, Long-Term Deferred Tax has averaged $36.9 million across 5 years, with a median of $38.3 million in 2024.
• Annual changes were most pronounced in 2022 — Long-Term Deferred Tax plunged 30.33% — and 2023, when it jumped 95.05%.
• Catalyst Pharmaceuticals' Long-Term Deferred Tax stood at $18.7 million in 2022, then jumped by 95.05% to $36.5 million in 2023, then gained by 25.83% to $46.0 million in 2024, then advanced by 14.76% to $52.8 million in 2025, then rose by 4.44% to $55.1 million in 2026.
• The last three Long-Term Deferred Tax figures came in at $55.1 million (Q1 2026), $52.8 million (Q4 2025), and $48.3 million (Q3 2025), per Business Quant data.